For adult patients with secondary HPT on dialysis

Do you need help paying for Sensipar®?

Review your insurance type to see which programs may help.

To learn more about
Amgen Assist
our reimbursement
and coverage support service,
click here >
Medicare Part D Dual-Eligible/Full LIS*
  • Full LIS patients have a co-pay of $7.40 or less (not subject to the donut hole).1
Standard Medicare Part D
  • You may be eligible for help from an independent co-pay foundation.
Private Insurance (Commercial)
  • The Sensipar® Pharmacy Card can lower your Sensipar® co-pay to as low as $5.00, if you qualify.
Self Pay
  • The Safety Net Foundation can help eligible patients receive Sensipar® at no cost.

If you aren’t sure which type of insurance you have, please call Amgen Assist® 1-800-272-9376

If you have any problems paying for your Sensipar® prescription at the pharmacy, discuss this with your dialysis care team at your next session.
To learn more about
Amgen Assist
our reimbursement
and coverage support service,
click here >
* The dual-eligible section includes Medicare/Medicaid, other Medicare patients who qualify for the Part D LIS, and government assistance. These patients have reduced cost sharing and are not subject to the coverage gap. Medicare Part D beneficiaries with full LIS status include dual eligible (Medicare/Medicaid) and those with income at or below 135% of the FPL. Beneficiaries with income between 135% and 150% of FPL can qualify for partial LIS; these patients pay 15% of drug cost until the total drug spend reaches $7,062 and then only up to $7.40 per prescription. Total drug spend represents cumulative costs paid by Medicare Part D and the patient for all covered prescription drugs. FPL amounts are subject to change. Amounts for Alaska and Hawaii can vary from other states and are usually slightly higher.
Standard Medicare Part D includes those who have purchased a Part D prescription plan but who have sufficient assets or income that disqualify them from receiving Medicaid or the LIS.
FPL = federal poverty level; LIS = low-income subsidy.


Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.

Sensipar® should not be used in adult patients with CKD who are not on dialysis because of an increased risk of low calcium levels.

Important Safety Information

  • Sensipar® (cinacalcet) treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges. Life threatening events and fatal outcomes associated with low calcium levels have been reported in patients treated with Sensipar®, including in children.
  • Low calcium levels may potentially result in abnormal heart rhythms, known as ventricular arrhythmia, and have been reported in patients taking Sensipar®.
  • Before starting Sensipar®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar® therapy.
  • Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar®.
  • While on Sensipar®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
  • Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar®.
  • Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
  • In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea.

If you have any questions about this information, be sure to discuss them with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 (332-1088).

Reference: 1. Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2014 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. April 2013. Available at: Accessed November 1, 2013.